



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

| APPLICATION NO. | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO. |
|-----------------|-------------|----------------------|---------------------|------------------|
| 10/523,618 | 04/25/2006 | Bruno Covelli | 29004-502 NATL | 1368 |

30623 7590 08/08/2007
MINTZ, LEVIN, COHN, FERRIS, GLOVSKY
AND POPEO, P.C.
ONE FINANCIAL CENTER
BOSTON, MA 02111

| |
|----------|
| EXAMINER |
|----------|

STROUD, JONATHAN R

| | |
|----------|--------------|
| ART UNIT | PAPER NUMBER |
|----------|--------------|

3709

| | |
|-----------|---------------|
| MAIL DATE | DELIVERY MODE |
|-----------|---------------|

08/08/2007

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary

Application No.

10/523,618

Applicant(s)

COVELLI, BRUNO

Examiner

Jonathan R. Stroud

Art Unit

3709

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 01 February 2005.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-15, 17-28 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-15 and 17-28 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on 01 February 2005 is/are: a) ☐ accepted or b) ☒ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☒ All b) ☐ Some * c) ☐ None of:
1. ☒ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date _____
- 4) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: _____

DETAILED ACTION

Specification

1. The disclosure is objected to because of the following informalities: on line 16, "hear" is believed to be in error for -- heart --. On line 26, "the receiving heart Under" is believed to be in error for -- the receiving heart. Under --.

Appropriate correction is required.

Drawings

2. The informal drawings are not of sufficient quality to permit examination. The images of Fig. 1 and Fig. 2 are not easily reproducible to the point where they are rendered incomprehensible. Accordingly, replacement drawing sheets in compliance with 37 CFR 1.121(d) are required in reply to this Office action. The replacement sheet(s) should be labeled "Replacement Sheet" in the page header (as per 37 CFR 1.84(c)) so as not to obstruct any portion of the drawing figures. If the changes are not accepted by the examiner, the applicant will be notified and informed of any required corrective action in the next Office action.

Claim Rejections - 35 USC § 103

3. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made

Art Unit: 3709

4. Rejections were made based on machine translations performed by Derwent, Google Translator, Babelfish and a standard Langenscheidt German-English English-German dictionary.
5. Claims 1-15 and 18-28 are rejected under 35 U.S.C. 103(a) as being anticipated by Hoerstrup DE 19919625 as claimed. Text between “ ” is present claims language, text between [] is examiner's reasoning for applying prior art. Translations are reproduced in italics for clarity.

Hoerstrup anticipates the device as disclosed and claimed and as follows:

“Providing a biodegradable support, colonizing the support with homologous fibroblasts and/or myofibroblasts cells to form a connective tissue matrix [abstract translation: *(i) colonizing a biodegradable carrier with homologous fibroblasts and/or myofibroblasts so as to give a connective tissue matrix*]; optionally colonizing the connective tissue matrix with endothelial cells [abstract translation: *(ii) colonizing the matrix with endothelial cells*]; and fixing of the matrix to a non-degradable or poorly degradable frame construction [the “carrier” as discussed above; furthermore, in the applicant's disclosure he sites that both the “non-degradable or poorly degradable frame construction” and “biodegradable support” can be constructed of PHA. Since both can be made of the same material, the use of the terms “biodegradable” and “poorly degradable” becomes non-limiting. Any part of the device can be considered either the frame or the carrier; the base of the device can be the frame, and the flaps the carrier, since they can be made of the same material.], before and/or after the fixing to the frame construction, the connective tissue matrix is introduced into a pulsatile flow chamber in which it can be

Art Unit: 3709

exposed to increasing flow rates, and the flow rate is increased continuously or discontinuously [abstract translation: *iii) introducing the matrix into a pulsating flow chamber (e.g. in a bioreactor) where it is subjected to a (dis)continuous flow rate*].

Furthermore, the addition of a "support" structure to Hoerstrup's design is obvious, since it can be made of the same material, and it has been held that the selection of a known material based on its suitability for its intended use supports a prima facie case for obviousness (Sinclair & Carroll Co. v. Interchemical Corp., 325 U.S. 327, 65 USPQ 297 (1945)), MPEP 2144.07) See Ionescu 4,441,216, Penny, III 4,816,029, and Rosen 4,345,340 for examples of stented heart valves.

The rearrangement of the steps in claim 2 does not change the process or product produced. It has been held that when the claimed and prior art products are identical in structure or composition, a prima facie case of either anticipation or obviousness has been established. See *In re Best*, 562 F.2d 1252, 1255, 195 USPQ 430, 433 (CCPA 1977). "When the PTO shows a sound basis for believing that the products of the applicant and the prior art are the same, the applicant has the burden of showing that they are not." *In re Spada*, 911 F.2d 705, 709, 15 USPQ2d 1655, 1658 (Fed. Cir. 1990). See MPEP 2112.01 [R-3].

6. Further, Hoerstrup teaches the device as discussed above where it is firmly connected the biodegradable support is a biodegradable polymer matrix or an acellular biological matrix, a polyglycolic acid (PGA), polylactic acid (PLA), polyhydroxyalkanoate (PHA), poly-4-hydroxybutyrate (P4HB) or a mixture of two or more of these polymers [[col. 2 ll. 65-68, col. 3 ll. 1-10], [*"...abovesaid biodegradable carrier includes PHA,*

Art Unit: 3709

PGA, PLA and/or P4HB and combinations thereof] the support has a polymer density of 40 to 120 mg/cm³ [col. 3 ll. 10-15], the support is a porous polymer having a pore size of 80 to 240 micrometers [col. 3 ll. 25-30] the fibers of the support have a diameter of 6 to 20 micrometers [col. 3 ll. 20-25], the support is the connective tissue framework of an animal or human heart valve [col. 3 ll. 33-39], the step of colonization with fibroblasts or myofibroblasts is repeated 3 to 14 times [col. 4 ll. 29 - 48] approximately 10^5 to 6×10^8 fibroblasts or myofibroblasts are employed per square centimeter of support/matrix [col. 4 ll. 10-20] the step of colonization with endothelial cells is repeated 3 to 14 times [col. 4 ll. 40-48], approximately 10^5 to 5×10^8 endothelial cells are employed per square centimeter of support/matrix [col. 4 ll. 40-48], the cells are human cells, which are autologous [col. 4 ll. 49-52], the frame construction is made of a biocompatible material [the carrier is constructed of the same material as the matrix ... i.e. PGA, PLA or PHA as described above], flow rates of 5 ml/min to 8,000 ml/min are established in the pulsatile flow chamber [col. 9 ll. 5-8: *range of 50-5,000 ml/min* anticipates the claimed range], the flow rate is increased over a period of 1 week to 12 weeks [col. 9 ll. 18-39, a 15-day increase falls within and anticipates the claimed range], the initial flow rate is 50 to 100 ml/min, the initial pulse frequency is 5 to 10 pulses/min, the flow rate is increased to 5,000 ml/min, the pulse frequency is increased to 180 pulses/min [col. 9 ll. 5-18], systemic pressures of 10 to 240 mm Hg are established in the pulsatile flow chamber [col. 9 ll. 40-44].

7. Claims 25-28 are anticipated by Hoestreup, since the heart valve claimed can be produced with the procedure as claimed above. See further col. 10 ll. 5-10 [collagen

Art Unit: 3709

density of 43-55 %] and col. 10 ll. 9-15 [translation: *heart valve designed to withstand the flow conditions within the human heart*].

Claim 17 is rejected under 35 U.S.C. 103(a) as being unpatentable over Hoerstrup in view of Rose 4,627,879. Hoerstrup teaches the invention as claimed and as discussed above, but fails to disclose the following claimed limitations taught by Rose: using fibrin adhesive to adhere the support structure to the seeded matrix [col. 1 ll. 14-49]. It would have been obvious to one of ordinary skill in the art at the time of invention to modify Hoerstrup in view of Rose, in order to achieve a biocompatible, biodegradable seal between the matrix and carrier that preserves the qualities of porous grafts and the achieves hemostasis, as taught by Rose [col. 1 ll. 14-49].

Conclusion

10. The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. See references cited.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jonathan R. Stroud whose telephone number is 571-270-3070. The examiner can normally be reached on Monday through Friday, 7:30 a.m. to 5 p.m.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ehud Gartenberg can be reached on (571) 272-4828. The fax phone

Art Unit: 3709

number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Jonathan Stroud/


EHUD GARTENBERG
SUPERVISORY PATENT EXAMINER

8/6/07